NorthWest Biotherapeutics Inc (NWBO)

[DoGood_DoWell]

All attacks on the company have been designed to create the impression that management is ineffective. Nothing could be further from the truth. Any other company facing such unprecedented levels of attack would have folded. Management has been heroic to stalwartly see the trial through and not sell out too early or unblind when there is more value to data with longer follow up. As mentioned, the pressures on the company have been intense, excruciating. Yet shareholders overwhelmingly vote with management, long shareholders controlling hundreds of millions of shares have never traded a single share, and the same few vocal naysayers are quite small in number compared to the loyal and quite knowledgeable longs. As the trial nears the finish line, this line of attack will likely paradoxically become more vocal. Like it does every year as we near the AGM. Fomenting this stock is a profitable sport for the unethical greedy who gain from the suffering of others. The proof of our good fortune in management is the Subbiah review showing every other immune CI trial failing and with terrible side effects. That no other company has come up with an effective or safe technology. That the platform can be used to treat any kind of solid tumor cancer. That they have focused on four countries, not just one, and have simultaneously developed manufacturing to scale up upon approval. They have successfully fought all lawsuits. They have patients with a variety of deadly cancers that are alive and healthy for a very long time who want to speak out and support the company.